Showing results (431-440 of 463) with videos related to

Sort By:
Pageof 47
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 3, 2026
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase studyCassie Nesbitt, Paul Sanfilippo, Chao Zhu, et al.
Neurology|March 5, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum DisorderPakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
Phytopathology|March 16, 2016
The U.S. Culture Collection Network Lays the Foundation for Progress in Preservation of Valuable Microbial ResourcesKevin McCluskey, Anne Alvarez, Rick Bennett, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2019
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotypeYuan Zhou, Suzi B Claflin, Jim Stankovich, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Brain : a Journal of Neurology|January 25, 2015
Genetic variants are major determinants of CSF antibody levels in multiple sclerosisAn Goris, Ine Pauwels, Marte W Gustavsen, et al.
Pageof 47